Several BTK inhibitors (e.g., acalabrutinib and ibruitinib, which blocks TLR7-dependent NF-κB activation in monocytes) have been shown to be potentially promising in treatment of patients with severe COVID-19. The gene discussed is TLR7; the disease is COVID-19.